{"nctId":"NCT00876447","briefTitle":"A Long-term Follow-up Study of Botulinum Toxin Type A in Patients With Overactive Bladder as a Result of Spinal Injury or Multiple Sclerosis","startDateStruct":{"date":"2009-01-01","type":"ACTUAL"},"conditions":["Overactive Bladder"],"count":397,"armGroups":[{"label":"Botulinum Toxin Type A 300U","type":"EXPERIMENTAL","interventionNames":["Biological: Botulinum Toxin Type A 300U"]},{"label":"Botulinum Toxin Type A 200U","type":"EXPERIMENTAL","interventionNames":["Biological: Botulinum Toxin Type A 200U"]}],"interventions":[{"name":"Botulinum Toxin Type A 300U","otherNames":["BOTOX®"]},{"name":"Botulinum Toxin Type A 200U","otherNames":["BOTOX®"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patient has participated in study 191622-515 or 191622-516 and the following criteria fulfilled:\n\n  * Patient completed at least 52 weeks in the preceding study.\n  * No longer than 6 months has elapsed since completion of the preceding study\n  * Patient has not received any prohibited medications during any intervening period between the preceding study and this long-term study.\n\nExclusion Criteria:\n\n* History or evidence of pelvic or urologic abnormality.\n* Previous or current diagnosis of bladder or prostate cancer.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Study Baseline in the Daily Average Number of Urinary Incontinence Episodes","description":"Urinary incontinence is defined as involuntary loss of urine as recorded in a patient bladder diary in the 3 consecutive days prior to each study visit for study 191622-094 (or 7 days prior to each visit in study 191622-515 or 191622-516). The number of incontinence episodes are averaged daily during this period. The initial study baseline is obtained from the patient bladder diary in the 7 consecutive days prior to the first treatment in either study 191622-515 or 191622-516. A negative number change from baseline indicates a reduction in incontinence episodes (improvement).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.4","spread":"2.54"},{"groupId":"OG001","value":"4.5","spread":"2.64"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.4","spread":"3.16"},{"groupId":"OG001","value":"-3.2","spread":"2.69"}]}]}]},{"type":"PRIMARY","title":"Change From Study Baseline in the Daily Average Number of Urinary Incontinence Episodes","description":"Urinary incontinence is defined as involuntary loss of urine as recorded in a patient bladder diary in the 3 consecutive days prior to each study visit for study 191622-094 (or 7 days prior to each visit in study 191622-515 or 191622-516). The number of incontinence episodes are averaged daily during this period. The initial study baseline is obtained from the patient bladder diary in the 7 consecutive days prior to the first treatment in either study 191622-515 or 191622-516. A negative number change from baseline indicates a reduction in incontinence episodes (improvement).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.5","spread":"2.62"},{"groupId":"OG001","value":"4.6","spread":"2.71"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.5","spread":"3.13"},{"groupId":"OG001","value":"-3.3","spread":"2.85"}]}]}]},{"type":"PRIMARY","title":"Change From Study Baseline in the Daily Average Number of Urinary Incontinence Episodes","description":"Urinary incontinence is defined as involuntary loss of urine as recorded in a patient bladder diary in the 3 consecutive days prior to each study visit for study 191622-094 (or 7 days prior to each visit in study 191622-515 or 191622-516). The number of incontinence episodes are averaged daily during this period. The initial study baseline is obtained from the patient bladder diary in the 7 consecutive days prior to the first treatment in either study 191622-515 or 191622-516. A negative number change from baseline indicates a reduction in incontinence episodes (improvement).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.4","spread":"2.33"},{"groupId":"OG001","value":"4.6","spread":"2.65"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.3","spread":"2.39"},{"groupId":"OG001","value":"-3.5","spread":"2.96"}]}]}]},{"type":"PRIMARY","title":"Change From Study Baseline in the Daily Average Number of Urinary Incontinence Episodes","description":"Urinary incontinence is defined as involuntary loss of urine as recorded in a patient bladder diary in the 3 consecutive days prior to each study visit for study 191622-094 (or 7 days prior to each visit in study 191622-515 or 191622-516). The number of incontinence episodes are averaged daily during this period. The initial study baseline is obtained from the patient bladder diary in the 7 consecutive days prior to the first treatment in either study 191622-515 or 191622-516. A negative number change from baseline indicates a reduction in incontinence episodes (improvement).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.4","spread":"2.13"},{"groupId":"OG001","value":"4.4","spread":"2.57"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.4","spread":"2.57"},{"groupId":"OG001","value":"-3.5","spread":"2.61"}]}]}]},{"type":"PRIMARY","title":"Change From Study Baseline in the Daily Average Number of Urinary Incontinence Episodes","description":"Urinary incontinence is defined as involuntary loss of urine as recorded in a patient bladder diary in the 3 consecutive days prior to each study visit for study 191622-094 (or 7 days prior to each visit in study 191622-515 or 191622-516). The number of incontinence episodes are averaged daily during this period. The initial study baseline is obtained from the patient bladder diary in the 7 consecutive days prior to the first treatment in either study 191622-515 or 191622-516. A negative number change from baseline indicates a reduction in incontinence episodes (improvement).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.1","spread":"2.34"},{"groupId":"OG001","value":"4.6","spread":"2.57"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.7","spread":"2.82"},{"groupId":"OG001","value":"-3.6","spread":"2.27"}]}]}]},{"type":"SECONDARY","title":"Change From Study Baseline in the Incontinence Quality of Life Instrument (I-QOL) Total Summary Score","description":"The I-QOL questionnaire is a validated, disease-specific quality of life (QOL) questionnaire containing 22 questions designed to measure the impact of urinary incontinence on patients' lives. Each question is answered on a 5-point scale (1 = worst QOL and 5 = best QOL). The scores are totaled over the 22 questions and normalized to a score of 0-100 (0 = worst QOL and 100= best QOL). The I-QOL total score is calculated by combining the 22-item subscores from the 3 I-QOL domains: Avoidance Limiting Behavior, Psychological Impact, and Social Embarrassment. The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-515 or 191622-516. Positive number changes from baseline indicate improved QOL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.9","spread":"18.19"},{"groupId":"OG001","value":"34.4","spread":"18.18"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32.3","spread":"26.07"},{"groupId":"OG001","value":"30.3","spread":"26.37"}]}]}]},{"type":"SECONDARY","title":"Change From Study Baseline in the Incontinence Quality of Life Instrument (I-QOL) Total Summary Score","description":"The I-QOL questionnaire is a validated, disease-specific quality of life (QOL) questionnaire containing 22 questions designed to measure the impact of urinary incontinence on patients' lives. Each question is answered on a 5-point scale (1 = worst QOL and 5 = best QOL). The scores are totaled over the 22 questions and normalized to a score of 0-100 (0 = worst QOL and 100= best QOL). The I-QOL total score is calculated by combining the 22-item subscores from the 3 I-QOL domains: Avoidance Limiting Behavior, Psychological Impact, and Social Embarrassment. The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-515 or 191622-516. Positive number changes from baseline indicate improved QOL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.3","spread":"18.17"},{"groupId":"OG001","value":"33.8","spread":"18.17"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.4","spread":"27.73"},{"groupId":"OG001","value":"33.5","spread":"26.23"}]}]}]},{"type":"SECONDARY","title":"Change From Study Baseline in the Incontinence Quality of Life Instrument (I-QOL) Total Summary Score","description":"The I-QOL questionnaire is a validated, disease-specific quality of life (QOL) questionnaire containing 22 questions designed to measure the impact of urinary incontinence on patients' lives. Each question is answered on a 5-point scale (1 = worst QOL and 5 = best QOL). The scores are totaled over the 22 questions and normalized to a score of 0-100 (0 = worst QOL and 100= best QOL). The I-QOL total score is calculated by combining the 22-item subscores from the 3 I-QOL domains: Avoidance Limiting Behavior, Psychological Impact, and Social Embarrassment. The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-515 or 191622-516. Positive number changes from baseline indicate improved QOL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.5","spread":"17.83"},{"groupId":"OG001","value":"34.8","spread":"18.95"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.8","spread":"28.96"},{"groupId":"OG001","value":"30.4","spread":"29.25"}]}]}]},{"type":"SECONDARY","title":"Change From Study Baseline in the Incontinence Quality of Life Instrument (I-QOL) Total Summary Score","description":"The I-QOL questionnaire is a validated, disease-specific quality of life (QOL) questionnaire containing 22 questions designed to measure the impact of urinary incontinence on patients' lives. Each question is answered on a 5-point scale (1 = worst QOL and 5 = best QOL). The scores are totaled over the 22 questions and normalized to a score of 0-100 (0 = worst QOL and 100= best QOL). The I-QOL total score is calculated by combining the 22-item subscores from the 3 I-QOL domains: Avoidance Limiting Behavior, Psychological Impact, and Social Embarrassment. The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-515 or 191622-516. Positive number changes from baseline indicate improved QOL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27.9","spread":"16.66"},{"groupId":"OG001","value":"35.5","spread":"17.70"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.4","spread":"31.77"},{"groupId":"OG001","value":"30.1","spread":"26.07"}]}]}]},{"type":"SECONDARY","title":"Change From Study Baseline in the Incontinence Quality of Life Instrument (I-QOL) Total Summary Score","description":"The I-QOL questionnaire is a validated, disease-specific quality of life (QOL) questionnaire containing 22 questions designed to measure the impact of urinary incontinence on patients' lives. Each question is answered on a 5-point scale (1 = worst QOL and 5 = best QOL). The scores are totaled over the 22 questions and normalized to a score of 0-100 (0 = worst QOL and 100= best QOL). The I-QOL total score is calculated by combining the 22-item subscores from the 3 I-QOL domains: Avoidance Limiting Behavior, Psychological Impact, and Social Embarrassment. The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-515 or 191622-516. Positive number changes from baseline indicate improved QOL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.0","spread":"16.13"},{"groupId":"OG001","value":"33.0","spread":"19.61"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.6","spread":"28.28"},{"groupId":"OG001","value":"27.1","spread":"24.54"}]}]}]},{"type":"SECONDARY","title":"Change From Study Baseline in Volume Per Void","description":"The total volume voided (voluntary or by catheterization) is recorded by the patient over a 24-hour period preceding the study visit. The average volume per voiding episode is derived by dividing the total volume collected in a 24-hour period by the total number of urinary episodes with volume recorded in the same 24-hour period. The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-515 or 191622-516. Positive number changes from baseline indicate improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"147.3","spread":"90.15"},{"groupId":"OG001","value":"154.2","spread":"96.54"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"133.8","spread":"137.23"},{"groupId":"OG001","value":"133.2","spread":"128.19"}]}]}]},{"type":"SECONDARY","title":"Change From Study Baseline in Volume Per Void","description":"The total volume voided (voluntary or by catheterization) is recorded by the patient over a 24-hour period preceding the study visit. The average volume per voiding episode is derived by dividing the total volume collected in a 24-hour period by the total number of urinary episodes with volume recorded in the same 24-hour period. The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-515 or 191622-516. Positive number changes from baseline indicate improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"149.8","spread":"91.03"},{"groupId":"OG001","value":"151.9","spread":"95.22"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"148.0","spread":"134.45"},{"groupId":"OG001","value":"135.1","spread":"127.62"}]}]}]},{"type":"SECONDARY","title":"Change From Study Baseline in Volume Per Void","description":"The total volume voided (voluntary or by catheterization) is recorded by the patient over a 24-hour period preceding the study visit. The average volume per voiding episode is derived by dividing the total volume collected in a 24-hour period by the total number of urinary episodes with volume recorded in the same 24-hour period. The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-515 or 191622-516. Positive number changes from baseline indicate improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"155.0","spread":"90.70"},{"groupId":"OG001","value":"149.6","spread":"91.12"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"166.9","spread":"133.59"},{"groupId":"OG001","value":"157.5","spread":"129.81"}]}]}]},{"type":"SECONDARY","title":"Change From Study Baseline in Volume Per Void","description":"The total volume voided (voluntary or by catheterization) is recorded by the patient over a 24-hour period preceding the study visit. The average volume per voiding episode is derived by dividing the total volume collected in a 24-hour period by the total number of urinary episodes with volume recorded in the same 24-hour period. The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-515 or 191622-516. Positive number changes from baseline indicate improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"159.7","spread":"89.37"},{"groupId":"OG001","value":"151.7","spread":"93.65"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"170.8","spread":"128.26"},{"groupId":"OG001","value":"147.3","spread":"122.09"}]}]}]},{"type":"SECONDARY","title":"Change From Study Baseline in Volume Per Void","description":"The total volume voided (voluntary or by catheterization) is recorded by the patient over a 24-hour period preceding the study visit. The average volume per voiding episode is derived by dividing the total volume collected in a 24-hour period by the total number of urinary episodes with volume recorded in the same 24-hour period. The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-515 or 191622-516. Positive number changes from baseline indicate improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"182.7","spread":"85.03"},{"groupId":"OG001","value":"140.8","spread":"91.32"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"163.5","spread":"106.44"},{"groupId":"OG001","value":"160.2","spread":"119.40"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":28,"n":185},"commonTop":["Urinary Tract Infection","Urinary Retention","Expanded Disability Status Scale Score Increased","Fall","Diarrhoea"]}}}